Actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial

Pulmonary Arterial Hypertension includes a heterogeneous group of disorders with a common genetic, pathological and hemodinamyc origin. It is characterized by a high pulmonary artery pressure due to a primary vascular disease, as a consequence of genetic and environmental factors. The common pathway...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zagolin B,Mónica, Wainstein G,Eduardo, Uriarte G,Polentzi
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2006
Materias:	Hypertension, pulmonary Prostaglandins Receptors, vascular endothelial growth factor Sildenafil
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000700015
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872006000700015
record_format	dspace
spelling	oai:scielo:S0034-988720060007000152006-08-29Actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterialZagolin B,MónicaWainstein G,EduardoUriarte G,Polentzi Hypertension, pulmonary Prostaglandins Receptors, vascular endothelial growth factor Sildenafil Pulmonary Arterial Hypertension includes a heterogeneous group of disorders with a common genetic, pathological and hemodinamyc origin. It is characterized by a high pulmonary artery pressure due to a primary vascular disease, as a consequence of genetic and environmental factors. The common pathway is a vascular imbalance towards vasoconstriction and proliferation inside the small vessels. According to the World Health Organization, 2003, Pulmonary Arterial Hypertension is classified as idiopathic, familiar or associated to connective tissue diseases, HIV, drugs, porto-pulmonary hypertension, congenital intracardiac shunts and others. The diagnosis is based in hemodynamics. Echocardiogram is a non invasive and right ventricular catheterization is an invasive diagnostic tool. Follow up is based on a clinical and functional assessment through functional class classification, dyspnea scores and 6-minute walking test. The prognosis is historically devastating but new therapies are changing the natural history of the disease. New treatments have demonstrated improvement in symptoms, hemodynamic profiles and survival. Intravenous, subcutaneous or inhaled prostanoids such as Epoprostenol, Treprostinil or Iloprost respectively have been approved for Pulmonary Arterial Hypertension treatment as well as oral endothelial receptor blockers. They are all considered first line treatments for arterial pulmonary hypertensive patients with even better benefits than lung transplantation. Phosphodiesterase inhibitors (Sildenafil), have been recently approved for the treatment of pulmonary arterial hypertensioninfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.134 n.7 20062006-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000700015es10.4067/S0034-98872006000700015
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Hypertension, pulmonary Prostaglandins Receptors, vascular endothelial growth factor Sildenafil
spellingShingle	Hypertension, pulmonary Prostaglandins Receptors, vascular endothelial growth factor Sildenafil Zagolin B,Mónica Wainstein G,Eduardo Uriarte G,Polentzi Actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial
description	Pulmonary Arterial Hypertension includes a heterogeneous group of disorders with a common genetic, pathological and hemodinamyc origin. It is characterized by a high pulmonary artery pressure due to a primary vascular disease, as a consequence of genetic and environmental factors. The common pathway is a vascular imbalance towards vasoconstriction and proliferation inside the small vessels. According to the World Health Organization, 2003, Pulmonary Arterial Hypertension is classified as idiopathic, familiar or associated to connective tissue diseases, HIV, drugs, porto-pulmonary hypertension, congenital intracardiac shunts and others. The diagnosis is based in hemodynamics. Echocardiogram is a non invasive and right ventricular catheterization is an invasive diagnostic tool. Follow up is based on a clinical and functional assessment through functional class classification, dyspnea scores and 6-minute walking test. The prognosis is historically devastating but new therapies are changing the natural history of the disease. New treatments have demonstrated improvement in symptoms, hemodynamic profiles and survival. Intravenous, subcutaneous or inhaled prostanoids such as Epoprostenol, Treprostinil or Iloprost respectively have been approved for Pulmonary Arterial Hypertension treatment as well as oral endothelial receptor blockers. They are all considered first line treatments for arterial pulmonary hypertensive patients with even better benefits than lung transplantation. Phosphodiesterase inhibitors (Sildenafil), have been recently approved for the treatment of pulmonary arterial hypertension
author	Zagolin B,Mónica Wainstein G,Eduardo Uriarte G,Polentzi
author_facet	Zagolin B,Mónica Wainstein G,Eduardo Uriarte G,Polentzi
author_sort	Zagolin B,Mónica
title	Actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial
title_short	Actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial
title_full	Actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial
title_fullStr	Actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial
title_full_unstemmed	Actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial
title_sort	actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial
publisher	Sociedad Médica de Santiago
publishDate	2006
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872006000700015
work_keys_str_mv	AT zagolinbmonica actualizacioneneldiagnosticoyterapeuticaenhipertensionpulmonararterial AT wainsteingeduardo actualizacioneneldiagnosticoyterapeuticaenhipertensionpulmonararterial AT uriartegpolentzi actualizacioneneldiagnosticoyterapeuticaenhipertensionpulmonararterial
_version_	1718436272074129408

Actualización en el diagnóstico y terapéutica en hipertensión pulmonar arterial

Ejemplares similares